8-K: Moleculin Hits MIRACLE Trial Milestone, Data Readout Nears

Moleculin Biotech announced the enrollment of its 45th subject in the pivotal Phase 2B/3 MIRACLE trial for R/R AML, setting the stage for a critical mid-2026 interim data unblinding.

Summary

• Moleculin Biotech, Inc. (MBRX) announced the enrollment of the 45th subject in its pivotal Phase 2B/3 MIRACLE trial.
• The trial evaluates Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukemia (R/R AML).
• This milestone triggers the final phase of preparation for the interim 45-subject data unblinding, which remains on track for mid-2026.
• Early blinded results from the first 30 patients showed a 40% composite complete remission rate (30% complete remission and 10% complete remission with partial hematologic recovery).
• Approximately 35% of subjects had previously failed venetoclax-based therapies, and many exhibited adverse genetic markers typically associated with poor outcomes.
• Enrollment continues in parallel towards the 90-subject threshold for Part A, expected in Q3 2026, with complete unblinding thereafter.
• The trial's adaptive design is intended to support a streamlined global registration pathway, potentially leading to accelerated approval based on the Complete Remission primary endpoint.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive clinical update, marking a significant step towards a pivotal data readout for a potentially transformative AML treatment, despite the acknowledged need for future financing.

Positives

• Achieved the 45-subject enrollment milestone in the pivotal Phase 2B/3 MIRACLE trial for R/R AML.
• Interim 45-subject data unblinding remains on track for mid-2026, representing a potentially defining inflection point for the Company.
• Early blinded results from the first 30 patients showed an encouraging 40% composite complete remission rate, despite a difficult-to-treat patient population (approximately 35% previously failed venetoclax-based therapies and many exhibited adverse genetic markers).
• The previous Phase 2 AML MB-106 clinical trial generated greater efficacy than any drug ever approved for relapsed or refractory AML.
• Over 100 patients treated to date with Annamycin without any associated cardiotoxicity, a common and severe side effect of currently prescribed anthracyclines.
• The MIRACLE trial's adaptive design is intended to support a streamlined global registration pathway and potential accelerated approval.
• Enrollment is accelerating towards the 90-subject threshold for Part A.
• Broader momentum across Moleculin's oncology pipeline, which includes ongoing and planned studies targeting pancreatic cancer, brain tumors, and soft tissue sarcoma.

Negatives

• Requires significant additional financing to conduct its clinical trials, for which the Company currently has no commitments.

Risks

• Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described.
• The milestones described assume the Company's ability to secure such financing on a timely basis.
• Expectations reflected in forward-looking statements may prove to have been materially different from the results expressed or implied by such statements.
• The Company relies on the reports of its expert with regard to the absence of cardiotoxicity, which is subject to ongoing validation.
• The dataset referenced is preliminary and subject to the review of data from future subjects in current and future clinical trials and long-term follow-up.
• Known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. Risk Factors in the most recently filed Form 10-K and updated in Form 10-Q filings and other public filings with the SEC.

Future Outlook

The company anticipates a critical interim data readout for the MIRACLE trial in mid-2026, which could be a defining inflection point. Enrollment will continue towards 90 subjects for Part A, expected in Q3 2026, with a second unblinding thereafter. The Phase 3 portion will commence once the optimum dose is determined, with the program remaining on track for potential accelerated approval based on the Complete Remission primary endpoint.

Management Comments

• "We believe this upcoming data readout represents the most important milestone in our history to date." Walter Klemp, Chairman and CEO of Moleculin.
• "This is a critical achievement for Moleculin and, more importantly, for patients facing relapsed or refractory AML." Walter Klemp.
• "Based on what we believe to be encouraging blinded results announced in February, we believe we are building real momentum toward what could be a transformative outcome." Walter Klemp.
• "Our Phase 2 AML MB-106 clinical trial generated greater efficacy than any drug ever approved for relapsed or refractory AML, and it contributed to the more than 100 patients treated to date without any associated cardiotoxicity." Walter Klemp.
• "What remains now is to demonstrate that a larger Phase 3 trial can produce results that will support new drug approval. The upcoming unblinding of the first 45 subjects should be a strong indicator of that potential." Walter Klemp.
• "A true next-generation anthracycline has long been sought by medical science and would rightly be considered a gamechanger, not just for AML but for a wide range of cancers. We now appear to be on the threshold of finding out whether this can become a reality." Walter Klemp.

Industry Context

StockSavvy.ai notes that the development of a "next-generation anthracycline" like Annamycin, designed to avoid multidrug resistance and cardiotoxicity, addresses significant unmet needs in oncology. The 40% preliminary remission rate in a difficult-to-treat R/R AML population, including those who failed venetoclax-based therapies, positions Annamycin as a potentially significant advancement in a field where new, effective, and well-tolerated treatments are highly sought after.

Comparison to Industry Standards

• The preliminary blinded aggregate outcomes of a 40% composite complete remission rate compare favorably to historical remission rates associated with cytarabine alone in relapsed or refractory acute myeloid leukemia.
• The Phase 2 AML MB-106 clinical trial generated greater efficacy than any drug ever approved for relapsed or refractory AML.
• Annamycin has been administered to over 100 patients without associated cardiotoxicity, a significant advantage over currently prescribed anthracyclines like doxorubicin or daunorubicin.

Stakeholder Impact

• Shareholders: Potential for significant value creation if the interim data readout is positive and leads to accelerated approval. However, dilution risk exists due to the acknowledged need for additional financing.
• Patients (R/R AML): Annamycin offers a potential new treatment option with high efficacy and a lack of cardiotoxicity, addressing a critical unmet medical need in a difficult-to-treat population.
• Medical Community: The development of a next-generation anthracycline could be a "gamechanger" for AML and other cancers, providing a new tool for oncologists.

Next Steps

• Final phase of preparation for the interim 45-subject data unblinding in mid-2026.
• Continued enrollment towards 90 total subjects to conclude Part A of MIRACLE, expected in Q3 2026.
• Complete unblinding of Part A data after 90 subjects.
• Commencement of the Phase 3 portion of the study once the optimum dose is determined.
• Potential accelerated approval pathway based solely on the Complete Remission primary endpoint.
• Ongoing and planned studies for other oncology pipeline candidates (pancreatic cancer, brain tumors, soft tissue sarcoma).

Key Dates

Recommendation

The achievement of the 45-subject enrollment milestone for a pivotal Phase 2B/3 trial in a challenging indication like R/R AML, coupled with encouraging early blinded remission rates (40%) and a strong safety profile (no cardiotoxicity in over 100 patients), positions Moleculin for a potentially transformative mid-2026 data readout. The adaptive trial design and potential for accelerated approval further de-risk the development pathway. While future financing is required, the significant clinical upside and the potential for Annamycin to be a "gamechanger" in AML outweigh this risk for a seasoned investor, suggesting a strong buy ahead of the critical data unblinding.

Keywords

Moleculin Biotech, MBRX, Annamycin, MIRACLE trial, AML, acute myeloid leukemia, relapsed refractory, R/R AML, AnnAraC, cytarabine, clinical trial, Phase 2B/3, oncology, cancer treatment, drug development, interim data, unblinding, remission rate, cardiotoxicity, FDA Project Optimus, accelerated approval